Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion, ...

The purchase is expected to complement Thermo’s clinical research services, as companies are conducting more clinical trials.

Cabaletta Bio ( ($CABA) ) has issued an update. On October 27, 2025, Cabaletta Bio announced positive clinical data and development updates from ...

BridgeBio Pharma’s analyst price target has ticked up, with the consensus fair value estimate rising from $66.32 to $66.47 per share. This modest upward revision reflects increased optimism about the ...

Investing.com -- Neumora Therapeutics Inc (NASDAQ:NMRA) stock jumped 8.4% in premarket trading Monday after the company reported positive preclinical data for its obesity drug candidate and received ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Citi's new price target for BioAge Labs implies a gain of about 32% from the stock's closing price on Oct. 24. Unfortunately, ...

Ionis Pharmaceuticals posts strong Q3 2025 results, raises revenue guidance, and highlights new launches and breakthrough clinical data.

Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed ...

Importantly, BGE-102 is an oral candidate. The current leaders in the anti-obesity market are administered via subcutaneous ...

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is one of the top long-term biotechnology stocks to buy. On October 17, Tonix Pharmaceuticals (NASDAQ:TNXP) presented encouraging preclinical data for ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...